Skip to main content
Endocrinology logoLink to Endocrinology
. 2008 Jul;149(7):3264–3266. doi: 10.1210/en.2008-0402

De-fense! De-fense! De-fense: Scavenging H2O2 While Making Cholesterol

Stavros C Manolagas 1
PMCID: PMC2453099  PMID: 18483146

It has been long appreciated that abnormal glucose, lipid, and bone metabolism, as well as atherosclerosis and neuronal degeneration, are common accompaniments of old age—often present as co-morbidities in the same individual. However, it is only recently that shared molecular pathogenetic mechanisms related to aging per se have been implicated in the development of these conditions. This forward stride is largely due to significant advances in our understanding of the biology of aging, genetic discoveries in animal models and humans, the demonstration of a similar function of the same genes in different organs, and better grasp of integrative physiology and pathophysiology.

To date the most durable and widely accepted mechanistic explanation of aging is oxidative stress. According to this theory, cellular stress caused by reactive oxygen species (ROS) is a major determinant of aging and life span (1). Approximately 90% of ROS arise in the mitochondria as byproducts of aerobic metabolism—the process that is fueled by nutrients such as glucose and is responsible for the formation of ATP. ROS are generated by the escape of somewhere between 0.1 and 2% of electrons passing through the electron transport chain. Escaped electrons are added to molecular oxygen to generate superoxide (O2·−), hydrogen peroxide (H2O2), and the hydroxyl radical (OH·−). A series of important discoveries highlighted in recent review articles (2,3,4) indicate that H2O2 is a critical signal for the replicative capacity of regenerative cells, as well as for apoptosis, for changes in gene expression leading to aging and aging-related diseases. Compared with (O2·−) and (OH·−), H2O2 has the highest oxidative activity, the highest stability, and the highest intracellular molar concentration. Importantly, proapoptotic signals including ROS release the adapter protein p66shc from an inhibitory complex in the inner mitochondria membrane. Active p66shc serves as a redox enzyme that catalyzes reduction of O2 to H2O2 through electron transfer from cytochrome c. H2O2 in turn causes opening of the mitochondrial permeability transition pore, swelling, and apoptosis.

To defend against the adverse effects of oxidative stress, cells have developed several intricate antioxidant defense mechanisms that involve both enzymatic reactions and altered gene transcription. Antioxidant enzymes include various isoforms of superoxide dismutase, which catalyzes the conversion of O2·− to H2O2, which in turn is converted to water and oxygen by catalases. Alternative mechanisms against oxidative stress involve thiol-reducing buffers consisting of oligopeptides with redox-active sulfhydryl moieties, the most abundant of which are glutathione (GSH) and thioredoxin. GSH peroxidase converts peroxides to harmless alcohols in a reaction in which the enzyme oxidizes GSH to the disulfide GSSG; and GSH reductase converts it back to GSH (5). A similar defense mechanism is provided by the peroxiredoxin family of enzymes, which use thioredoxin as substrate. Some of these enzymes are localized inside the mitochondria, whereas others are located in the cytosol or the extracellular space.

In this issue of Endocrinology, Lu and co-workers (6) report an elegant series of studies demonstrating that 3β-hydroxysteroid-Δ24 reductase (DHCR24), also known as Diminuto/Seladin-1, is a H2O2 scavenger that protects cells from oxidative stress-induced apoptosis. Interestingly, whereas catalase is exclusively localized in the peroxisome and the major isoforms of GSH peroxidase and peroxiredoxin are mainly in the cytosol, DHCR24 is localized in the endoplasmic reticulum. Consistent with this localization, DHCR24 exerted cytoprotective effects in response to both H2O2 and endoplasmic reticulum stress-induced by tunicamycin. Based on this unique localization, the authors suggest that different antioxidant enzymes may play distinct roles in H2O2 elimination in an organelle-specific manner.

DHCR24 has another biologic role. It is an indispensable catalyst of the final step in cholesterol biosynthesis. Derangements of lipid metabolism including cholesterol accumulation and lipid oxidation in association with oxidative stress have been demonstrated in neuronal cell membranes in patients with Alzheimer’s disease. Specifically, 4-hydroxynonenal (4-HNE), a breakdown product of oxidized fatty acids is increased in brain tissues of Alzheimer’s disease patients (7). 4-HNE itself is highly reactive, and it induces oxidative stress via glutathione depletion. Moreover, DHCR24 is highly expressed in neuronal cells throughout mammalian brains, and its expression is decreased in neurons within selective vulnerable regions of Alzheimer’s disease (8). Hence, scavenging of H2O2 by an enzyme that also makes cholesterol makes sense in teleological terms.

Members of the FoxO transcription factors have recently emerged as another major cell defense mechanism against oxidative damage by virtue of their ability to up-regulate the transcription of free radical scavenging enzymes such as manganese superoxide dismutase, catalase, and DNA damage repair genes such as Gadd45 (3,4). FoxOs shuttle between the cytoplasm and the nucleus depending on the phosphorylation of specific sites by distinct sets of kinases. Phosphorylation of FoxOs in response to growth factors such as insulin and IGFs, via phosphatidylinositol 3-kinase and Akt kinases, favors their retention in the cytoplasm. On the other hand, phosphorylation of FoxOs (in different sites) in response to oxidative stress results in their translocation into the nucleus where they transactivate several cyclins, cyclin-dependent kinase inhibitors, DNA repair, and apoptosis control genes, as well as antioxidant enzymes. FoxOs not only promote mammalian cell survival by inducing cell cycle arrest and quiescence in response to oxidative stress, but they also regulate longevity in model organisms.

β-Catenin, a critical component of the canonical Wnt signaling pathway, may be a pivotal molecule in defense against oxidative stress by serving as a cofactor of FoxOs. Like oxidative stress, the Wnt/β-catenin signaling pathway affects several biological processes ranging from embryonic development, patterning, and postembryonic stem cell fate, to bone formation and insulin secretion in adulthood. β-Catenin mediates canonical Wnt signaling by binding to and activating members of the T-cell factor (TCF) transcription factor family. Several lines of recent evidence have strongly suggested a linkage among the age-associated oxidative stress, FoxOs, Wnt/β-catenin signaling, osteoblastogenesis, adipogenesis, osteoporosis, and several features of the metabolic syndrome and atherosclerosis.

Oxidative stress (corresponding with decreased GSH reductase activity) is a pivotal pathogenetic factor of age-related bone loss and strength in mice, leading to, among other changes, an increase in osteoblast and osteocyte apoptosis and a decrease in osteoblast number and the rate of bone formation. Estrogens or androgens decrease oxidative stress in bone cells and the loss of these sex steroids accelerates the involution of the skeleton by age-associated oxidative stress (9). Moreover, skeletal involution with advancing age in mice is also associated with the diversion of a limited pool of β-catenin from TCF- to FoxO-mediated transcription in osteoblastic cells (10). Consistent with these findings, attenuation of Wnt-mediated transcription, resulting from autosomal-dominant missense mutations in LRP6 or LRP5, coreceptors for the Wnt-signaling pathway, has been linked genetically to osteoporosis. These mutations have also been linked to coronary artery disease in the same large kindreds as well as several features of the metabolic syndrome including hyperlipidemia, hypertension, and diabetes (11,12). Based on all these lines of evidence, we have proposed that antagonism of Wnt signaling by oxidative stress with increasing age may be a common molecular mechanism contributing to the development not only of involutional osteoporosis, but several pathologies such as hyperlipidemia, atherosclerosis, and insulin resistance, all of which become more prevalent with advancing age (Ref. 13 and Fig. 1). The same mechanism may be operational in neurodegenerative disorders like Alzheimer’s (14).

Figure 1.

Figure 1

Increased oxidative stress with advancing age antagonizes the beneficial effects of Wnt/β-catenin signaling on bone, glucose, and lipid metabolism, by diverting β-catenin from TCF- to FoxO-mediated transcription. LEF, Lymphoid enhancer-binding factor 1.

Closer to the subject of lipid oxidation and the causation of disease, a vast literature dating back to 1979 suggests a critical role for lipid oxidation in the development of atherogenesis (15). Furthermore, extensive epidemiological evidence, including an association between coronary artery disease and low bone mineral density has more recently indicated that atherosclerosis and osteoporosis may be mechanistically linked (16,17,18). Indeed, the levels of Alox15—a lipoxygenase that generates oxidized lipids—are inversely related to bone mass in mice (19,20). Furthermore, activation of peroxisome proliferator-activating receptor-γ by oxidized lipids (or the synthetic drug ligand rosiglitazone) promotes the development of adipocytes at the expense of osteoblasts in vitro (21). In addition, rosiglitazone induces bone loss in mice and humans, and this effect is associated with increased marrow adiposity, decreased osteoblast number and bone formation rate, and increased osteoblast and osteocyte apoptosis (22,23,24). Alox15 adds oxygen to polyunsaturated fatty acids and in the process the catalytic iron is reduced to ferrous. This hydroperoxide product decomposes into a hydroxy derivative to generate a stable oxidation product, which can then bind to peroxisome proliferator-activating receptor-γ to exert the skeletal effects. In the process of this decomposition, a hydroxy radical is released. This has two important consequences. First, the catalytic iron motif is oxidized to reactivate alox15. Second, it adds to the redox burden of the cell, which can generate by nonenzymatic means newly oxidized fatty acids. During aging, alox15 activity increases as does lipid oxidation; and this probably contributes to the increased osteoblast apoptosis and other cellular changes leading to osteoporosis. Furthermore, 4-HNE is as potent as H2O2 in inducing p66shc phosphorylation and osteoblastic cell apoptosis (25).

The discovery in the article by Lu et al. (6) that DHCR24, an essential enzyme in cholesterol biosynthesis, is also an H2O2 scavenging enzyme adds a further element to the complex array of cellular mechanisms involved in defense against oxidative stress. At this stage, it is unknown whether DHCR24 deficiency plays a role in the pathogenesis of atherosclerosis, the metabolic syndrome, or osteoporosis, but these possibilities certainly need to be explored. Defense, defense, and more defense clearly seem to be part of Nature’s game plan in dealing with oxidative stress. Defects in any one of the components involved could have far-reaching consequences for aging and age-related degenerative diseases.

Acknowledgments

I thank Robert Jilka, Ph.D. for helpful discussions of the ideas presented in this editorial and Robyn DeWall for assistance in the preparation of the manuscript.

Footnotes

This work was supported by the National Institutes of Health (P01AG13918 and R01AR51187), a Merit Review grant by the Department of Veterans Affairs, and Tobacco Settlement funds provided by the University of Arkansas for Medical Sciences.

See article p. 3267.

Abbreviations: DHCR2, 43β-Hydroxysteroid-Δ24 reductase; 4-HNE, 4-hydroxynonenal; ROS, reactive oxygen species; TCF, T-cell factor.

References

  1. Balaban RS, Nemoto S, Finkel T 2005 Mitochondria, oxidants, and aging. Cell 120:483–495 [DOI] [PubMed] [Google Scholar]
  2. Giorgio M, Trinei M, Migliaccio E, Pelicci PG 2007 Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? Nat Rev Mol Cell Biol 8:722–728 [DOI] [PubMed] [Google Scholar]
  3. Russell SJ, Kahn CR 2007 Endocrine regulation of ageing. Nat Rev Mol Cell Biol 8:681–691 [DOI] [PubMed] [Google Scholar]
  4. Sharpless NE, DePinho RA 2007 How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol 8:703–713 [DOI] [PubMed] [Google Scholar]
  5. Dickinson DA, Forman HJ 2002 Glutathione in defense and signaling: lessons from a small thiol. Ann NY Acad Sci 973:488–504 [DOI] [PubMed] [Google Scholar]
  6. Lu X, Kambe F, Cao X, Kozaki Y, Kaji T, Ishii T, Seo H 2008 3β-Hydroxysteroid-Δ24 reductase is a hydrogen peroxide scavenger, protecting cells from oxidative stress-induced apoptosis. Endocrinology 149:3267–3273 [DOI] [PubMed] [Google Scholar]
  7. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP 2004 Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci USA 101:2070–2075 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Greeve I, Hermans-Borgmeyer I, Brellinger C, Kasper D, Gomez-Isla T, Behl C, Levkau B, Nitsch RM 2000 The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer’s disease-associated neurodegeneration and oxidative stress. J Neurosci 20:7345–7352 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, Kousteni S, O'Brien CA, Bellido T, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC 2007 Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 282:27285–27297 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC 2007 Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting β-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem 282:27298–27305 [DOI] [PubMed] [Google Scholar]
  11. Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP 2007 LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315:1278–1282 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Saarinen A, Saukkonen T, Somer M, Laine CM, Toiviainen-Salo S, Lehesjoki A, Mäkitie O LRP5 mutations are associated with osteoporosis, impaired glucose tolerance and hypercholesterolemia. J Bone Miner Res 22:S112 (Abstract 281) [Google Scholar]
  13. Manolagas SC, Almeida M 2007 Gone with the Wnts: β-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 21:2605–2614 [DOI] [PubMed] [Google Scholar]
  14. Decarolis NA, Wharton Jr KA, Eisch AJ 2008 Which way does the Wnt blow? Exploring the duality of canonical Wnt signaling on cellular aging. Bioessays 30:102–106 [DOI] [PubMed] [Google Scholar]
  15. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM 2004 The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 45:993–1007 [DOI] [PubMed] [Google Scholar]
  16. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V 2004 Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 89:4246–4253 [DOI] [PubMed] [Google Scholar]
  17. Farhat GN, Cauley JA, Matthews KA, Newman AB, Johnston J, Mackey R, Edmundowicz D, Sutton-Tyrrell K 2006 Volumetric BMD and vascular calcification in middle-aged women: the Study of Women’s Health across the Nation. J Bone Miner Res 21:1839–1846 [DOI] [PubMed] [Google Scholar]
  18. Marcovitz PA, Tran HH, Franklin BA, O'Neill WW, Yerkey M, Boura J, Kleerekoper M, Dickinson CZ 2005 Usefulness of bone mineral density to predict significant coronary artery disease. Am J Cardiol 96:1059–1063 [DOI] [PubMed] [Google Scholar]
  19. Klein RF, Allard J, Avnur Z, Nikolcheva T, Rotstein D, Carlos AS, Shea M, Waters RV, Belknap JK, Peltz G, Orwoll ES 2004 Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science 303:229–232 [DOI] [PubMed] [Google Scholar]
  20. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H 2004 PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113:846–855 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL 2002 Divergent effects of selective peroxisome proliferator-activated receptor-γ2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143:2376–2384 [DOI] [PubMed] [Google Scholar]
  22. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC 2004 Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183:203–216 [DOI] [PubMed] [Google Scholar]
  23. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B 2004 Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401–406 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL 2005 Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146:1226–1235 [DOI] [PubMed] [Google Scholar]
  25. Jilka RL, Almeida M, Wynne R, Han L, Manolagas SC 2007 Oxidized metabolites of polyunsaturated fatty acids stimulate osteoblast apoptosis via both PPARγ-dependent and -independent mechanisms. J Bone Miner Res 22:S90 (Abstract S002) [Google Scholar]

Articles from Endocrinology are provided here courtesy of The Endocrine Society

RESOURCES